Willke R - Search Results

1

Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.

Zhang Z, Mahoney EM, Kolm P, Spertus J, Caro J, Willke R, Weintraub WS. Zhang Z, et al. Among authors: willke r. Am J Cardiovasc Drugs. 2010;10(1):55-63. doi: 10.2165/11319940-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20104935

2

Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.

Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B. Weintraub WS, et al. Among authors: willke r. Circulation. 2005 Mar 8;111(9):1106-13. doi: 10.1161/01.CIR.0000157146.86758.BC. Epub 2005 Feb 21. Circulation. 2005. PMID: 15723981 Clinical Trial.

3

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ. Xenakis JG, et al. Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000. Pharmacoeconomics. 2011. PMID: 21452908

4

Comparative effectiveness and cost-effectiveness analyses frequently agree on value.

Glick HA, McElligott S, Pauly MV, Willke RJ, Bergquist H, Doshi J, Fleisher LA, Kinosian B, Perfetto E, Polsky DE, Schwartz JS. Glick HA, et al. Health Aff (Millwood). 2015 May;34(5):805-11. doi: 10.1377/hlthaff.2014.0552. Health Aff (Millwood). 2015. PMID: 25941282

5

Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.

Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Ramsey SD, et al. Value Health. 2015 Mar;18(2):161-72. doi: 10.1016/j.jval.2015.02.001. Value Health. 2015. PMID: 25773551 Free article. Review.

6

Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.

Getsios D, Marton JP, Revankar N, Ward AJ, Willke RJ, Rublee D, Ishak KJ, Xenakis JG. Getsios D, et al. Pharmacoeconomics. 2013 Sep;31(9):767-80. doi: 10.1007/s40273-013-0070-5. Pharmacoeconomics. 2013. PMID: 23821436

7

Smoking, smoking cessation and smoking relapse patterns: a web-based survey of current and former smokers in the US.

Yeomans K, Payne KA, Marton JP, Merikle EP, Proskorovsky I, Zou KH, Li Q, Willke RJ. Yeomans K, et al. Among authors: willke rj. Int J Clin Pract. 2011 Oct;65(10):1043-54. doi: 10.1111/j.1742-1241.2011.02758.x. Int J Clin Pract. 2011. PMID: 21923845

8

Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation.

Menzin J, Marton JP, Menzin JA, Willke RJ, Woodward RM, Federico V. Menzin J, et al. BMC Med Res Methodol. 2012 Jun 25;12:87. doi: 10.1186/1471-2288-12-87. BMC Med Res Methodol. 2012. PMID: 22731620 Free PMC article.

9

Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A. Barbieri M, et al. Among authors: willke r. Value Health. 2005 Jan-Feb;8(1):10-23. doi: 10.1111/j.1524-4733.2005.03070.x. Value Health. 2005. PMID: 15841890 Free article. Review.

10

Estimating country-specific cost-effectiveness from multinational clinical trials.

Willke RJ, Glick HA, Polsky D, Schulman K. Willke RJ, et al. Health Econ. 1998 Sep;7(6):481-93. doi: 10.1002/(sici)1099-1050(199809)7:6<481::aid-hec353>3.0.co;2-k. Health Econ. 1998. PMID: 9809707

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters